Welcome to our dedicated page for Moderna SEC filings (Ticker: MRNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Moderna, Inc. (NASDAQ: MRNA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports, proxy statements and other key documents filed with the U.S. Securities and Exchange Commission. For a commercial-stage biotechnology company focused on mRNA medicines, these filings offer detailed insight into its financial condition, governance, pipeline priorities and material agreements.
Investors can review Form 8-K current reports where Moderna describes significant events such as quarterly and semiannual financial results, new credit facilities and major business updates. For example, the company has used Form 8-K to report its entry into a $1.5 billion Credit and Guaranty Agreement, to furnish quarterly earnings press releases and to highlight pipeline and strategy updates presented at its Analyst Day.
The page also includes proxy materials such as the DEF 14A, where Moderna explains proposals submitted to shareholders, outlines compensation and incentive structures, and discusses governance matters. A recent definitive proxy statement describes a one-time stock option exchange program for non-Executive Committee employees, including its rationale, design features and potential impact on shareholders.
Through these filings, users can examine Moderna’s capital structure and liquidity arrangements, including the terms of its credit facility, guarantees by subsidiaries and financial covenants such as minimum liquidity requirements. They can also see how the company communicates its strategic priorities, cost-efficiency plans and cash breakeven targets in official documents.
Stock Titan enhances this information by organizing filings chronologically and by type, and by pairing them with AI-powered summaries that highlight the main points from lengthy documents. This helps readers quickly understand the significance of Moderna’s 8-Ks, proxy statements and other SEC reports without having to parse every page, while still allowing full access to the underlying filings for deeper analysis.
Moderna, Inc. Chief Financial Officer James M. Mock reported several equity compensation transactions. On March 1, 2026, he received a grant of 37,639 stock options and 49,569 restricted stock units (RSUs), with options and RSUs vesting 25% on March 1, 2027 and the remainder in twelve quarterly installments.
On February 27, 2026, multiple RSU awards converted into common stock on a one-for-one basis, and shares totaling 160, 375, and 4,788 were disposed of at $51.71 per share to cover tax withholding obligations. Following these transactions, Mock continued to hold common stock and derivative awards directly.
Moderna, Inc. president Stephen Hoge reported option exercises and a stock sale. On February 23, 2026, he exercised stock options covering 111,679 and 48,330 shares at an exercise price of $19.15 per share, receiving the same number of common shares. On the same date, he sold 160,009 Moderna common shares at an average price of $48.84 per share in an open-market transaction effected under a Rule 10b5‑1 trading plan adopted on November 13, 2025. After these transactions, he directly held 1,457,427 Moderna common shares. Separate indirect holdings include 4,116 shares held by Valhalla, LLC and 151,933 shares held by a trust for the benefit of his spouse and children, for which he disclaims beneficial ownership except to any pecuniary interest.
Moderna reports on its mRNA-focused business, highlighting three commercial vaccines—Spikevax and mNEXSPIKE for COVID-19 and mRESVIA for RSV—and 2025 revenue of $1.9 billion, largely from COVID vaccines. The company emphasizes a broad pipeline across infectious disease, oncology and rare diseases, including 35 therapeutic and vaccine programs, six in late-stage development.
Key programs include the flu vaccine mRNA-1010 and flu+COVID combo mRNA-1083 under regulatory review, a norovirus candidate mRNA-1403 in a large Phase 3 trial, and rare disease therapies for propionic acidemia and methylmalonic acidemia in registrational paths. In oncology, individualized therapy intismeran autogene (mRNA-4157), partnered with Merck, has shown sustained recurrence-free survival benefit in high-risk melanoma and expanded into multiple Phase 2 and 3 trials.
Moderna details a global manufacturing network in the U.S., UK, Canada and Australia, purpose-built facilities for personalized cancer vaccines, and heavy investment in platform, AI and digital tools to speed design, development and production. The filing also outlines extensive business risks, including regulatory uncertainty, competition, manufacturing complexity, cybersecurity and continued net losses in 2024 and 2025.
Moderna’s Chief Financial Officer, James M. Mock, reported equity compensation activity involving company common stock. On February 11, 2026, he acquired 2,630 shares at $0 through the vesting of performance-based restricted stock units granted on February 28, 2023.
On the same date, 1,278 shares were disposed of at $41.99 to satisfy tax withholding obligations linked to this vesting. After these transactions, Mock directly owned 45,224 shares of Moderna common stock.
Klinger Shannon Thyme reported multiple insider transaction types in a Form 4 filing for MRNA. The filing lists transactions totaling 3,964 shares at a weighted average price of $41.99 per share. Following the reported transactions, holdings were 55,861 shares.
Moderna president Stephen Hoge reported equity award vesting and related tax withholding transactions in Moderna, Inc. common stock. On February 11, 2026, he acquired 4,884 shares at $0 from the vesting of performance-based restricted stock units granted on February 28, 2023. On the same date, 2,362 shares were disposed of at $41.99 to satisfy tax withholding obligations, leaving 1,457,427 shares held directly. He also has indirect ownership of 4,116 shares through Valhalla, LLC and 151,933 shares held by a trust for the benefit of his spouse and children, for which he disclaims beneficial ownership except for any pecuniary interest.
Moderna, Inc. chief executive Stephane Bancel reported equity compensation activity involving company common stock. On February 11, 2026, performance-based restricted stock units granted on February 28, 2023 vested, resulting in an acquisition of 11,271 common shares at $0. On the same date, 5,450 shares were disposed of at $41.99 per share to cover tax withholding obligations related to this vesting, a non‑open‑market tax-withholding disposition. Following these transactions, Bancel directly held 6,187,791 common shares. The filing also reports indirect holdings of 9,210,686 shares through Boston Biotech Ventures and 6,564,880 shares through OCHA LLC, for which he disclaims beneficial ownership except for any pecuniary interest.
Moderna reported fourth quarter and full-year 2025 results showing sharply lower COVID vaccine revenue but reduced losses and a strong cash balance. Fourth quarter revenue was $678 million with a GAAP net loss of $826 million, or $(2.11) per share. For 2025, revenue was $1.9 billion, down 40% from 2024, and the GAAP net loss narrowed to $2.8 billion, or $(7.26) per share. Operating expenses fell meaningfully, with full-year research and development down 31% to $3.1 billion and selling, general and administrative costs down 13% to $1.0 billion, reflecting cost discipline and the wind-down of large Phase 3 respiratory programs. Cash, cash equivalents and investments totaled $8.1 billion as of December 31, 2025, including a $600 million draw on a $1.5 billion credit facility. For 2026, Moderna targets up to 10% revenue growth from 2025, expects cost of sales of about $0.9 billion, research and development expenses of about $3.0 billion and selling, general and administrative expenses of about $1.0 billion, with projected year-end cash and investments of $5.5 to $6.0 billion. The company highlighted late-stage pipeline milestones, including regulatory reviews for its seasonal flu and flu/COVID vaccines outside the U.S., a U.S. Refusal-to-File letter for its flu programs with a requested Type A meeting, fully enrolled Phase 3 norovirus and multiple oncology trials, and a registrational rare disease program with key data readouts expected in 2026.